CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|61|5|1591-1602

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.61, Iss.5, 2015-05, pp. : 1591-1602

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibition of myeloid cell leukemia‐1: Association with sorafenib‐induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft

By  

HEAD & NECK: JOURNAL FOR THE SCIENCES & SPECIALTIES OF THE HEAD AND NECK, Vol. 37, Iss. 9, 2015-09 ,pp. : 1326-1335

John Wiley & Sons Inc

Access to resources Recommend Favorite

Response to ‘Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after patients on antiprogrammed cell death‐1 inhibition with nivolumab’

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 32, Iss. 2, 2018-02 ,pp. : e61-e62

John Wiley & Sons Inc

Access to resources Recommend Favorite

Identification of Responders to Sorafenib in Hepatocellular Carcinoma: Is Tumor Volume Measurement the Way Forward?

By  

Oncology, Vol. 86, Iss. 4, 2014-04 ,pp. : 191-198

Karger

Access to resources Recommend Favorite

Meta‐Analysis of the Risk of Immune‐Related Adverse Events With Anticytotoxic T‐Lymphocyte‐Associated Antigen 4 and Antiprogrammed Death 1 Therapies

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 103, Iss. 2, 2018-02 ,pp. : 318-331

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Retrospective Comparison with Previously Known Prognostic Models

By  

Oncology, Vol. 80, Iss. 3-4, 2011-06 ,pp. : 167-174

Karger

Access to resources Recommend Favorite